Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, McKesson (NYSE:MCK) -- a distributor of pharmaceuticals, medical supplies, and information technology to pharmacies and health-care providers -- has earned a coveted five-star ranking.

With that in mind, let's take a closer look at McKesson's business and see what CAPS investors are saying about the stock right now.

McKesson facts

Headquarters (founded)

San Francisco (1833)

Market Cap

$14.07 billion


Health-Care Distributors

Trailing-12-Month Revenue

$106.59 billion


CEO John Hammergren (since 2001)

CFO Jeffrey Campbell (since 2004)

Return on Equity (average, last three years)



Cardinal Health (NYSE:CAH)

AmerisourceBergen (NYSE:ABC)

CAPS Members Bullish on MCK Also Bullish on

Johnson & Johnson (NYSE:JNJ)

General Electric (NYSE:GE)

CAPS Members Bearish on MCK Also Bearish on

Citigroup (NYSE:C)

Microsoft (NASDAQ:MSFT)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

Over on CAPS, some 96% of the 462 members who have rated McKesson believe the stock will outperform the S&P 500 going forward. These bulls include BMunkers and adavisclan.

Just two days ago, BMunkers touched on some firsthand dealings with the drug dealer:

[McKesson] is doing a good job expanding their business services to clients across the country. I currently work at a payer system where we utilize many of their software products. If we see universal health care, [McKesson] will still be a major provider for the services that the payers, government or private, need.

In an earlier pitch, adavisclan expands on the supertrend moving in McKesson's direction:

The health care distribution sector is likely to continue growing with the aging population. Should national health care become a reality more people will have access to distributors such as McKesson. They continue to generate and grow their free cash flow (which I believe is the life blood of any company) allowing for internal capital funding in these tight times. They have a solid balance sheet which current prices seem to be undervaluing.

What do you think about McKesson, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. McKesson is a Motley Fool Stock Advisor pick, Johnson & Johnson is an Income Investor selection, and Microsoft is a choice of Inside Value. The Fool's disclosure policy always gets a perfect score.